What is Oramed Pharmaceuticals Inc.'s (ORMP) StockRank?

MoatMap's StockRank for Oramed Pharmaceuticals Inc. (ORMP) is 58/100, with a Hold signal. This is a composite score combining Quality (57), Value (35), and Momentum (60) factor ranks across MoatMap's 20,000+ stock universe.

Does Oramed Pharmaceuticals Inc. have an economic moat?

Oramed Pharmaceuticals Inc. (ORMP) has a Quality factor score of 57/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Oramed Pharmaceuticals Inc. a buy, hold, or sell?

MoatMap's current signal for Oramed Pharmaceuticals Inc. (ORMP) is Hold, based on a StockRank of 58/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Oramed Pharmaceuticals Inc. in?

Oramed Pharmaceuticals Inc. (ORMP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ORMP

HOLD

Oramed Pharmaceuticals Inc. · Healthcare · United States · $165M · Avg Vol: $2M/d

StockRank

Get insider-trade alerts

P/E (TTM)

1.5x

ROE

58.2%

D/E

0.0x

Dividend %

6.1%

COMPANY DESCRIPTION

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company pioneering oral drug delivery systems, notably an oral insulin capsule for diabetes. Its proprietary POD™ technology aims to transform injectable treatments into convenient oral alternatives, offering significant potential market disruption. Oramed is a biotech player developing innovative solutions for chronic diseases.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR	TTM	2026E	Fwd CAGR
Revenue	2.7M	2.7M	1.3M	0	2.0M	-7.3%	—	—	—
EPS	-0.78	-0.94	0.14	-0.48	1.53	230.6%	2.65	2.36	54.0%
Shares	35.3M	39.6M	40.3M	39.9M	39.3M	+11.3%	40.9M	—	—
Debt	0.5M	0.9M	51.6M	0.4M	0.8M	11.5%	0.8M	—	—
Equity	115.8M	151.8M	163.8M	146.3M	199.7M	14.6%	—	—	—
Op CF	-21.2M	-27.9M	-10.3M	-8.4M	-9.1M	—	-8.5M	—	—
Inv CF	-23.8M	30.2M	-73.0M	105.8M	5.4M	—	—	—	—
Fin CF	102.9M	10.8M	52.0M	-52.0M	-4.7M	—	—	—	—

Loading 1Y...

PRICE (1Y)+7.5%

SMA 50SMA 200

$4.16

RSI (14)

43.1

52W High

$5.19

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

35.6%97.9

ROE

58.2%97.6

GP/Assets

0.0%10.1

Op. Margin

0.0%41.3

FCF/Assets

0.1%46.2

Piotroski

439.0

Int. Cover

—N/A

D/E Ratio

0.00x90.5

Current Ratio

6.45x77.8

Value

P/E (TTM)

1.5x25.0

EV/EBITDA

-7.3x25.0

P/FCF

658.1x2.6

P/B

0.7x92.3

P/S

—0.3

Div Yield

6.1%95.8

Momentum

52W High %

80%70.5

RS 6M

15%83.8

SMA 50/200

1.23x91.0

EPS Rev 4W

0.0%62.6

EPS Rev 12W

0.0%56.8

EPS Improve

-103%4.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$165M

P/E (Forward)

-51.3x

Gross Margin

0.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ORMP are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ORMP	Oramed Pharmaceuticals Inc.(you)	$165M	58	HOLD
FBIO	Fortress Biotech, Inc.	$111M	59	HOLD
AGEN	Agenus Inc.	$249M	61	HOLD
CSBR	Champions Oncology, Inc.	$85M	58	HOLD
ABEO	Abeona Therapeutics Inc.	$345M	59	HOLD
FENC	Fennec Pharmaceuticals Inc.	$347M	54	HOLD
OKUR	OnKure Therapeutics, Inc.	$166M	39	HOLD
DTIL	Precision BioSciences, Inc.	$188M	40	HOLD
IMUX	Immunic, Inc.	$182M	38	HOLD
NAGE	Niagen Bioscience, Inc.	$256M	73	BUY

Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.6%